Improved Clinical Outcomes During Long-term Osilodrostat Treatment of Cushing Disease With Normalization of Late-night Salivary Cortisol and Urinary Free Cortisol
2024

Better Outcomes with Osilodrostat in Cushing Disease

Sample size: 160 publication 10 minutes Evidence: high

Author Information

Author(s): John Newell-Price, Maria Fleseriu, Rosario Pivonello, Richard A. Feelders, Mônica R. Gadelha, André Lacroix, Przemysław Witek, Anthony P. Heaney, Andrea Piacentini, Alberto M. Pedroncelli, Beverly M. K. Biller

Primary Institution: University of Sheffield, Oregon Health & Science University, Università Federico II di Napoli, Erasmus Medical Center, Universidade Federal do Rio de Janeiro, Centre hospitalier de l’Université de Montréal, Medical University of Warsaw, University of California, Los Angeles, Recordati SpA, Recordati AG, Massachusetts General Hospital

Hypothesis

Does simultaneous normalization of late-night salivary cortisol and mean urinary free cortisol in patients with Cushing disease treated with osilodrostat lead to better clinical outcomes than controlling either parameter alone?

Conclusion

Normalizing both late-night salivary cortisol and mean urinary free cortisol in patients with Cushing disease treated with osilodrostat leads to improved long-term outcomes.

Supporting Evidence

  • 85% of patients had uncontrolled cortisol levels at baseline.
  • 48.6% achieved control of both cortisol levels after 72 weeks.
  • Improvements in cardiovascular/metabolic parameters were greatest in patients with both cortisol levels controlled.
  • Quality of life improved significantly in patients with controlled cortisol levels.

Takeaway

This study shows that for people with Cushing disease, getting both their nighttime and daily cortisol levels back to normal helps them feel better and stay healthier.

Methodology

Data from two phase III osilodrostat studies were pooled and analyzed, focusing on changes in cardiovascular/metabolic parameters, physical manifestations, and quality of life across different patient subgroups.

Potential Biases

Potential bias due to differences in study design and the primary endpoint focusing on mean urinary free cortisol normalization.

Limitations

The analysis had a small number of patients with only late-night salivary cortisol control and differences in osilodrostat exposure between studies.

Participant Demographics

Median age was 39 years, with 80.6% female and a high proportion having persistent or recurrent disease.

Statistical Information

P-Value

p<0.05

Confidence Interval

95% CI for time to first normalization: LNSC 82.0 days, mUFC 35.0 days, both 335.0 days.

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1210/jendso/bvae201

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication